Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization

Objectives Millions of patients worldwide are treated with therapeutic monoclonal antibodies. These biological therapeutics can be immunogenic, resulting in anti-drug antibody formation which leads to loss of response. Fully human biological agents, such as the anti-tumour necrosis factor α (anti-TNFα) antibody adalimumab, are considered to be weakly immunogenic, but anti-adalimumab antibodies (AAA) were recently detected in more than half of treated patients with rheumatoid arthritis (RA) within 28 weeks of treatment. A study was undertaken to determine the mechanism by which AAA lead to loss of response. Methods The specificity of the repertoire of AAA was investigated in a cohort of 50 AAA-positive RA patients. Inhibition experiments using TNFα and patient-derived anti-adalimumab monoclonal antibodies were performed. Results The antibody response against adalimumab is highly restricted: Fab fragments of a single monoclonal antibody specific for the idiotype of adalimumab inhibited 98.65% (25th–75th percentiles: 98.25–99.90) of the total anti-adalimumab reactivity in serum from 50 AAA-positive patients. The anti-adalimumab response was confined to the TNFα binding region of adalimumab, thereby neutralising its therapeutic efficacy. In line with this restricted specificity, small immune complexes were found in the circulation of AAA-forming patients. Conclusions The humoral immune response against adalimumab is highly restricted and limited to the idiotype of the therapeutic antibody. All antibodies result in functional neutralisation of the drug, thereby providing a mechanism by which AAA formation leads to clinical non-response.

[1]  L. Aarden,et al.  A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. , 2010, Journal of immunological methods.

[2]  B. Dijkmans,et al.  Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation , 2009, Annals of the rheumatic diseases.

[3]  C. Hack,et al.  Interleukin-8 in sepsis: relation to shock and inflammatory mediators , 1992, Infection and immunity.

[4]  B. Dijkmans,et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[5]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[6]  A. Verma The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL , 2008 .

[7]  L. Aarden,et al.  Immunology of DNA. IV. Quantitative aspects of the Farr assay. , 1976, Journal of immunological methods.

[8]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[9]  L. Mayer,et al.  Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease , 2010, Expert review of clinical immunology.

[10]  Rob Kaptein,et al.  Enzyme Free Cloning for high throughput gene cloning and expression , 2006, Journal of Structural and Functional Genomics.

[11]  B. Dijkmans,et al.  Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[12]  J. V. van Mourik,et al.  Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. , 1995, Experimental cell research.

[13]  Jerne Nk Towards a network theory of the immune system. , 1974 .

[14]  H. Jansen,et al.  Fel d 1-specific IgG antibodies induced by natural exposure have blocking activity in skin tests. , 1996, International archives of allergy and immunology.

[15]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[16]  B. Dijkmans,et al.  Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. , 2011, Arthritis and rheumatism.

[17]  L. Aarden,et al.  Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. , 2008, Current opinion in immunology.

[18]  N K Jerne,et al.  Towards a network theory of the immune system. , 1973, Annales d'immunologie.

[19]  P. V. van Riel,et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[20]  N. K. Jerne,et al.  The Generative Grammar of the Immune System , 1993, The EMBO journal.

[21]  L. Aarden,et al.  Differential effect of drug interference in immunogenicity assays. , 2011, Journal of immunological methods.

[22]  J. O'dell,et al.  State-of-the-art: rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[23]  B. Dijkmans,et al.  The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept , 2010, Annals of the rheumatic diseases.

[24]  C. Werner‐Favre,et al.  Limiting dilution assay for human B cells based on their activation by mutant EL4 thymoma cells: total and anti‐malaria responder B cell frequencies , 1987, European journal of immunology.

[25]  D. Veale,et al.  Psoriatic Arthritis Management Update – Biotherapeutic Options , 2009, The Journal of Rheumatology.

[26]  Fiona Adair,et al.  The immunogenicity of therapeutic proteins , 2002 .